Abstract

In the last three decades, technological advancements in health services have notably enhanced the detection and treatment of diseases, including cancer. This progress is particularly evident in the research and application of cancer biomarkers for early detection and risk assessment, aiming to lower cancer fatalities. These biomarkers represent a cost-effective alternative to traditional diagnostic methods like CT scans, though they have yet to achieve the reliability needed for clinical use. This thesis explores the development, validation, and quality control of cancer biomarkers, examining market trends in genomics, proteomics, and diagnostic technologies. The potential for biomarkers to offer less invasive and more affordable diagnostic options could lead to significant healthcare savings. Highlighting this potential, the National Cancer Institute's Early Detection Research Network has initiated a project focused on enhancing cancer cell biomarker identification, driven by individual researchers' efforts. This initiative reflects the growing emphasis on prevention over treatment in the fight against cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call